AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Why Church & Dwight Shares Are Falling Today
Church & Dwight Q4 net sales beat estimates, but Specialty Products' segment registered 9.2% sales decrease. Adjusted EPS in the quarter was $0.65, in line with the analyst consensus.
LyondellBasell Reports Mixed Q4 Results, Warns On Headwinds From Slow Demand
LyondellBasell Industries reported lower Q4 revenues of $9.93B. Adjusted EPS was $1.26, below consensus of $1.31. Outlook for 2024 includes continued challenges, low ethane costs, and uncertain China demand. Operating rates will be adjusted to global demand.
What’s Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?
Bristol Myers Squibb reports Q4 revenues of $11.48 billion, up 1% YoY. Eliquis and Opdivo sales drive growth, offsetting Revlimid decline.
New York’s Weed Disaster, Virginia’s Alcohol Model And Kentucky’s GOP Hurdles, Plus Hawaii And Florida Updates
New York's Cannabis Rollout: A Rocky Start
Exxon’s Q4 Surprise: Beats Earnings Expectations Despite Revenue Dip, Embarks On Bold EV And LNG Ventures
Exxon Mobil (XOM) reported Q4 FY23 adjusted net profit of $9.96 billion, or $2.48 per share, beating consensus estimates. Improved profits result from favorable derivative impacts, increased volume on key assets.
Deckers Outdoor Analysts Boost Their Forecasts After Strong Earnings
Deckers Outdoor Corporation (NYSE: DECK) reported better-than-expected third-quarter financial results on Thursday.
Why Is Charter Communications Stock Trading Lower Friday?
Charter Communications reported Q4 revenue growth of 0.3%, missing EPS consensus. Residential internet customers decreased, EBITDA margin expanded. Expects higher Capex in 2024.
Why Is Health Insurance Plan Provider Cigna Stock Trading Higher Today?
Cigna's robust Q4 2023 performance with $51.15 billion in sales, up 12% Y/Y. Dive into the growth of Cigna Healthcare, Evernorth Health Services.